Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03683719 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema
A Phase 2 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 258
- Enrollment target
NCT03683719 is a Phase 2 study that has completed, run by LEO Pharma. The registered enrollment target is 258 participants.
The verdict
NCT03683719, a Phase 2 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 258 participants
- Enrollment target
Study Summary
The purpose of this research trial was to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects chronic hand eczema. This was judged by a range of assessments that rate the severity and extent of chronic hand eczema and its symptoms, as well as general health status and quality of life.
Interventions
- DRUG Delgocitinib cream
- DRUG Delgocitinib cream vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2018-11-28 |
| Est. Completion | 2020-04-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03683719
The ClinicalTrials.gov registry entry for NCT03683719 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 258 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Delgocitinib cream is the first listed.
NCT03683719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03683719 about?
NCT03683719 is a clinical study titled "Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema". The purpose of this research trial was to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects chronic hand eczema. This was judged by a range of assessments that rate the severity and extent of ...
What is the current status of trial NCT03683719?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 258 participants. The study started on 2018-11-28. Estimated completion is 2020-04-20.
What interventions are being tested in trial NCT03683719?
The interventions under investigation include: Delgocitinib cream (DRUG), Delgocitinib cream vehicle (DRUG).
Who is sponsoring clinical trial NCT03683719?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.